Administration of zoledronic acid enhances the effects of docetaxel on growth of prostate cancer in the bone environment

@article{Brubaker2005AdministrationOZ,
  title={Administration of zoledronic acid enhances the effects of docetaxel on growth of prostate cancer in the bone environment},
  author={Kristen D. Brubaker and Lisha G. Brown and Robert L. Vessella and Eva Corey},
  journal={BMC Cancer},
  year={2005},
  volume={6},
  pages={15 - 15}
}
After development of hormone-refractory metastatic disease, prostate cancer is incurable. The recent history of chemotherapy has shown that with difficult disease targets, combinatorial therapy frequently offers the best chance of a cure. In this study we have examined the effects of a combination of zoledronic acid (ZOL), a new-generation bisphosphonate, and docetaxel on LuCaP 23.1, a prostate cancer xenograft that stimulates the osteoblastic reaction when grown in the bone environment. Intra… CONTINUE READING

From This Paper

Figures, tables, and topics from this paper.

Citations

Publications citing this paper.
Showing 1-10 of 37 extracted citations

Prostate Cancer

Methods in Molecular Biology • 2018

Docetaxel with or without zoledronic acid for castration-resistant prostate cancer

International Urology and Nephrology • 2014
View 1 Excerpt

References

Publications referenced by this paper.
Showing 1-10 of 48 references

Zoledronic acid exhibits inhibitory effects on osteoblastic and osteolytic metastases of prostate cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research • 2003
View 5 Excerpts
Highly Influenced

The role of bisphosphonates in the treatment of prostate cancer

CC Parker
BJU Int • 2005
View 1 Excerpt

Similar Papers

Loading similar papers…